Latest RGEN news

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Business Wire · Thu, 10 Sep 2026 16:12:00 -0400

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whether t.

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · Wed, 09 Sep 2026 16:47:06 -0400

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

Zacks Investment Research · Thu, 27 Aug 2026 12:35:43 -0400

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Zacks Investment Research · Thu, 27 Aug 2026 05:31:07 -0400

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

5 Biotech Stocks Worth Adding to Your Portfolio Now

Zacks Investment Research · Wed, 26 Aug 2026 11:20:19 -0400

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

GlobeNewsWire · Wed, 26 Aug 2026 07:30:00 -0400

WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET.

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.

24/7 Wall Street · Tue, 25 Aug 2026 07:15:43 -0400

On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.

Market information is provided for research and visualization and is not investment advice.